(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual revenue growth rate of 9.78% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Pacific Biosciences Of California's revenue in 2026 is $160,030,000.On average, 9 Wall Street analysts forecast PACB's revenue for 2026 to be $53,293,037,627, with the lowest PACB revenue forecast at $50,224,292,950, and the highest PACB revenue forecast at $56,911,547,292. On average, 9 Wall Street analysts forecast PACB's revenue for 2027 to be $61,235,122,789, with the lowest PACB revenue forecast at $56,920,865,343, and the highest PACB revenue forecast at $64,673,483,475.
In 2028, PACB is forecast to generate $65,148,704,058 in revenue, with the lowest revenue forecast at $37,166,597,986 and the highest revenue forecast at $77,749,814,540.